Ozempic & Visceral Fat: Clinical Evidence & Genetic Context

Last reviewed: May 30, 2026

Last updated: May 30, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, GLP-1 receptor agonists including semaglutide have demonstrated the ability to reduce visceral adipose tissue in clinical research. A 2023 study in Diabetes Care found that semaglutide reduced visceral fat by approximately 24% over 68 weeks, independent of subcutaneous fat loss.

Visceral fat—the metabolically active fat surrounding your organs—carries distinct health risks including insulin resistance and inflammation. Understanding whether you're genetically predisposed to accumulate visceral fat versus subcutaneous fat, and how your body responds to GLP-1 signaling, may help create a more targeted treatment strategy with your provider.

What Makes Visceral Fat Different From Other Body Fat

Visceral adipose tissue is metabolically distinct from subcutaneous fat. It secretes inflammatory cytokines, impairs hepatic insulin sensitivity, and correlates more strongly with cardiovascular disease risk, metabolic syndrome, and type 2 diabetes than total body weight.

GLP-1 medications appear to preferentially reduce visceral fat stores. This selective reduction may explain why some patients experience metabolic improvements (lower triglycerides, improved glucose control) that exceed what would be predicted from weight loss alone.

Clinical Evidence: How GLP-1 Medications Target Visceral Adiposity

Multiple randomized controlled trials have measured visceral fat changes using computed tomography or magnetic resonance imaging. The evidence supports a consistent finding: GLP-1 agonists reduce visceral fat more efficiently than diet and exercise alone.

The mechanism involves GLP-1 receptor signaling in the brain and gut, reducing appetite and food intake, while also enhancing energy expenditure and improving lipid metabolism in visceral adipose tissue itself.

Study/Trial	Medication	Duration	Visceral Fat Change	Key Finding
Diabetes Care (2023)	Semaglutide	68 weeks	−24% reduction	Greater visceral than subcutaneous fat loss
SUSTAIN-6 (2016)	Semaglutide	157 weeks	Significant reduction	Cardiovascular benefit independent of weight
LEADER (2016)	Liraglutide	160 weeks	Modest reduction	Liver fat and insulin sensitivity improved
Observational data	Tirzepatide	12-52 weeks	Enhanced reduction	Dual GIPR/GLP1R mechanism shows greater effect

Genetic Predisposition and Visceral Fat Distribution Patterns

Certain genetic variants influence where your body preferentially stores fat and how efficiently your body responds to GLP-1 signaling. The FTO gene variant rs9939609 and MC4R variant rs17782313 are associated with increased visceral adiposity risk and appetite dysregulation.

Your GIPR genetic variants may inform how sensitive your system is to GLP-1 and GIP signaling, potentially describing your pathway-level genetic baselines. This predisposition context should always be interpreted with your healthcare provider as part of a comprehensive metabolic assessment.

Who Benefits Most and What to Discuss With Your Provider

GLP-1 therapy may be particularly relevant if imaging or biomarkers indicate elevated visceral fat burden, metabolic syndrome features, or glucose dysregulation. Individuals with family history of type 2 diabetes or premature cardiovascular disease are reasonable candidates for provider evaluation.

Before starting any GLP-1 medication, your provider should assess kidney function, thyroid status, pancreatitis history, and metabolic markers (triglycerides, liver enzymes, fasting glucose). Your genetic predisposition profile can add context to these clinical findings without replacing standard medical evaluation.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test reveals your predispositions in key peptide pathway genes—GIPR, FTO, and MC4R—that may help provide context for how your body accumulates and mobilizes visceral fat. This information can complement your provider's clinical assessment and imaging findings.

The genetic test does not predict your exact response to any specific GLP-1 medication. Instead, it identifies genetic patterns that may increase visceral fat risk or influence appetite regulation, allowing for a more informed discussion about whether GLP-1 therapy aligns with your metabolic profile.

When combined with biomarkers (liver enzymes, triglycerides, fasting glucose, visceral fat imaging if available), your genetic predisposition context can support a more personalized conversation with your provider about treatment goals, expected timelines, and ongoing monitoring.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Why is visceral fat treated as more dangerous than the fat you can pinch?

The article says visceral adipose tissue is metabolically distinct from subcutaneous fat: it secretes inflammatory cytokines, impairs hepatic insulin sensitivity, and correlates more strongly with cardiovascular disease risk, metabolic syndrome and type 2 diabetes than total body weight does. That is why it treats visceral fat as its own target rather than a byproduct of overall weight.

How much visceral fat reduction did the 2023 Diabetes Care analysis report for semaglutide?

The article cites approximately 24 percent reduction in visceral fat over 68 weeks, described as independent of subcutaneous fat loss. Its summary of that study emphasises greater visceral than subcutaneous fat loss as the key finding. The article uses this to argue GLP-1 medications appear to preferentially reduce visceral stores rather than trimming fat evenly.

How do researchers actually measure visceral fat change in these trials?

The article says multiple randomized controlled trials have measured visceral fat changes using computed tomography or magnetic resonance imaging. That imaging is what allows the separation of visceral from subcutaneous fat that the article's central claim depends on. Without it, only total weight change would be visible, which the article argues understates the metabolic benefit.

Did liraglutide show the same visceral fat effect as semaglutide in these studies?

No. The article's summary lists LEADER from 2016 as showing only a modest reduction with liraglutide, alongside improvements in liver fat and insulin sensitivity. That contrasts with the 24 percent figure it reports for semaglutide. Observational tirzepatide data is described as showing enhanced reduction, which the article attributes to its dual-receptor mechanism.

What should a provider check before starting a GLP-1 aimed at visceral fat?

The article says your provider should assess kidney function, thyroid status, pancreatitis history, and metabolic markers including triglycerides, liver enzymes and fasting glucose. It suggests this therapy may be particularly relevant when imaging or biomarkers indicate an elevated visceral fat burden, metabolic syndrome features, or glucose dysregulation. Standard medical evaluation is not replaced by any of it.

Related Reading

• Is Belly Fat Linked To My Genetic Makeup
• Lifemd Ozempic
• Eden Ozempic
• Ro Ozempic

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.